CHPA and PCPC Comments Regarding Content and Format of Labeling for Human Nonprescription Drug Products Share page: Docket Number: FDA-2022-D-1837 Download Document Issues: OTC Medicines Other Issues Labeling Related Posts Press Releases and Statements CHPA Commends Lawmakers for Urging FDA to Protect the Rx-OTC-Switch Pathway Apr 11, 2025 Press Releases and Statements House Leaders Prioritize OMUFA Renewal, CHPA Welcomes Progress Apr 1, 2025 Press Releases and Statements CHPA Statement on Senate Confirmation of Dr. Makary as FDA Commissioner Mar 25, 2025